Literature DB >> 30470295

Evaluation of Surrogate End Points for Progression to ESKD: Necessary and Challenging.

Lesley A Inker1, Hiddo L Heerspink2.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30470295     DOI： 10.1053/j.ajkd.2018.08.017

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  3 in total

1.  Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis.

Authors:  Radko Komers; Ulysses Diva; Jula K Inrig; Andrea Loewen; Howard Trachtman; William E Rote
Journal:  Kidney Int Rep       Date:  2020-01-08

2.  State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.

Authors:  Julia J Scialla; Jessica Kendrick; Jaime Uribarri; Csaba P Kovesdy; Orlando M Gutiérrez; Elizabeth Yakes Jimenez; Holly J Kramer
Journal:  Am J Kidney Dis       Date:  2020-08-06       Impact factor: 8.860

3.  Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial).

Authors:  Jonathan Barratt; Brad Rovin; Ulysses Diva; Alex Mercer; Radko Komers
Journal:  Kidney Int Rep       Date:  2019-08-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.